Table 4.
Reported obesity-related comorbidities.
| All n = 36,837 | Males n = 17,934 (48.7%) | Females n = 18,903 (51.3%) | P | |
|---|---|---|---|---|
| Type 2 DM/ IGT | 429 (1.2%) | 220 (1.2%) | 209 (1.1%) | 0.279 |
| OSA | 313 (0.8%) | 188 (1.0%) | 125 (0.7%) | <0.001 |
| PTC | 53 (0.1%) | 18 (0.1%) | 35 (0.2%) | 0.032 |
| Hypertension | 194 (0.5%) | 125 (0.7%) | 69 (0.4%) | <0.001 |
| Dyslipidemia | 549 (1.5%) | 243 (1.4%) | 306 (1.6%) | 0.037 |
| NAFLD | 189 (0.5%) | 92 (0.5%) | 97 (0.5%) | 0.998 |
| SCFE | 7 (<0.001%) | 3 (<0.001%) | 4 (<0.001%) | 0.999 |
| PCO | 8 (<0.001%) | 8 (<0.001%) |
Data are presented as number (percent). P values represent Pearson’s chi-square tests.
DM diabetes mellitus, IGT impaired glucose tolerance, OSA obstructive sleep apnea, PTC pseudotumor cerebri, NAFLD non-alcoholic fatty liver disease, SCFE slipped capital femoral epiphysis, PCO polycystic ovary syndrome.